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Background: We describe the rationale and protocol for a randomized noninferiority controlled trial (RCT) to
determine if the Flexi-T380(+) copper intrauterine contraceptive device (IUD) is comparable in terms of effectiveness
and expulsion rates to the most common Canadian IUD currently in use, NovaT-200, when placed immediately
after a first-trimester abortion.
Methods/Design: Consenting women choosing to use an IUD after an abortion for a pregnancy of less than 12 weeks
of gestation will be randomized to device-type groups to receive immediate post-abortion placement of either a
Flexi-T380(+) IUD, a device for which no current evidence on expulsion or effectiveness rates is available, or the
Nova-T200 IUD, the only other brand of copper IUD available in Canada at the time of study initiation. The primary
outcome measure is IUD expulsion rate at 1 year. Secondary outcomes include: pregnancy rate, method continuation
rate, complication rates (infection, perforation), and satisfaction with contraceptive method. A non-intervention group of
consenting women choosing a range of other post-abortion contraception methods, including no contraception, will be
included for comparison of secondary outcomes. Web-based contraception satisfaction questionnaires, clinical records,
and government-linked health administrative databases will be used to assess primary and secondary outcomes.
Discussion: The RCT design, combined with access to clinical records at all provincial abortion clinics, and to
information in provincial single-payer linked administrative health databases, birth registry, and hospital records, offers a
unique opportunity to determine if a novel IUD has a comparable expulsion rate to that of the current standard IUD in
Canada, in addition to the first opportunity to determine pregnancy rate and method satisfaction at 1 year post-abortion
for women choosing a range of post-abortion contraceptive options. We highlight considerations of design,
implementation, and evaluation of the first trial to provide rigorous evidence for the effectiveness of current Canadian
IUDs when inserted after first-trimester abortion.
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This randomized non-inferiority controlled trial (RCT)
will examine the effectiveness of post-abortion contra-
ception by determining whether a new type of copper
intrauterine device (IUD) in Canada has a comparable
effectiveness and safety profile to the most commonly
used Canadian IUD. Clinical experience suggests that
expulsion rates may vary significantly between devices,
but we have been unable to find any published evidence
estimating expulsion rate or pregnancy rate for this new
IUD. Our results will provide some evidence of whether
the new IUD is comparable with the current standard,
and provide the first prospective rigorous evaluation of
effectiveness at 1 year for post-abortion contraceptive
methods currently available in Canada.
Nearly a third of Canadian women have at least one
abortion [1]. Annually about 100,000 abortions are per-
formed in Canada [2]. In 2009, at least 30.7% of these
were repeat abortions [3]. Women having repeat abor-
tions are more likely to be from ethno-cultural minor-
ities, to report problems with a male partner, to have a
lower level of education, and to have other children at
home [4,5]. Thus, research to delineate methods to pre-
vent recurrent unwanted pregnancies in this vulnerable
population is a high priority. Ames [6] found a 5-year re-
peat abortion rate of 9.4% for Canadian women who had
an IUD (Flexi-T380(+)W; Prosan International BV.
Arnhem, The Netherlands) [7] placed immediately after
a first-trimester abortion. However, this retrospective
study was only able to determine the recurrent abortion
rate of women returning to the index abortion clinic;
thus, it is possible that the number of pregnancies was
significantly higher than the number of repeat abortions
reported. Even so, the reported repeat abortion rate of
9.4% is significantly higher than would be expected
based on evidence for the post-abortion effectiveness of
a copper IUD [8,9]. Overall 5-year pregnancy rate for
IUD users is estimated to be less than 2% [10-12], or a
repeat abortion rate of 35 per 1000 women-years of
follow-up for women with other models of IUD placed
post-abortion [13]. Indeed, the placement of copper IUD
types available in other jurisdictions as an effective
contraception method following a first-trimester (before
12 weeks of gestational age) abortion is well supported
by systematic reviews [8,14].
The only copper IUDs available in Canada at the time
this study began were the Nova-T (Nova-T200W; Bayer Inc,
Canada), and two Flexi-T devices (Flexi-T300W and Flexi-
T380(+)W; both Prosan International BV) [7]. Canadian
physicians report higher rates of expulsion with the Flexi-T
devices [6,15] and yet many prefer the Flexi-T380(+) be-
cause evidence supports copper devices with a surface area
of 380 mm as being more effective than those with an area
of 200 mm [10,14,16-19]. We found no reports in theliterature describing the expulsion rates or effectiveness for
the Flexi-T devices, although reported outcomes for
NovaT200 are available [16-19].
This RCT will determine if the Flexi-T380(+) copper
IUD (referred to hereafter as ‘FlexiT’) is comparable with
the most common Canadian copper IUD currently in
use, the NovaT-200 copper IUD (referred to as the
‘NovaT’), when placed immediately after a first-trimester
abortion. Additionally, we will report the first rigorous
evidence for the effectiveness of, and satisfaction with,




This prospective non-inferiority randomized controlled
study will recruit women at the time of an abortion at ges-
tational age of less than 12 weeks (first trimester). Con-
senting women choosing to use an IUD post-abortion will
be randomized to type of device, and women choosing
other post-abortion contraceptive methods, or no method
of contraception, will be enrolled in a non-intervention,
observational arm. Primary outcome will be rate of expul-
sion at 1 year. Secondary outcomes will include rates for
pregnancy; complications such as infection or perforation;
continuation of, and satisfaction with, the chosen contra-
ceptive method as determined at 1, 2, 3, 4 and 5 years; and
expulsion rate for each type of copper IUD at 2, 3, 4 and
5 years.
Sample-size justification for comparing expulsion rates
for the NovaT and FlexiT
Our aim in this non-inferiority study is to provide evi-
dence that the expulsion rate for the Flexi-T does not
exceed that of the Nova-T by more than 10%. The ra-
tionale for this choice rests on the assumption that the
detection rate for IUD expulsions is at least 85% [20],
which implies that the loss in efficacy of a device due to
expulsions is less than 0.15 times its expulsion rate,
and correspondingly, that any difference in efficacy
between devices is less than 0.15 times the difference
in expulsion rates. Thus differences of 10% in expul-
sion rates translate into differences in efficacy of 1.5%
or less.
We calculated power calculations for non-inferiority test-
ing following the approach described by Blackwelder [21]
using the on-line calculator provided by S. Patten [22].
Our null hypothesis is:
H0: FlexiT expulsion rate ≥ NovaT expulsion rate + 10%.
This formula requires specification of the problem in
terms of success proportions (that is, those not experien-
cing expulsion by 1 year). We will assume the rate of
those not experiencing expulsion will be 96% for the
Nova-T [17-19] and 92% for the Flexi-T. Thus, we
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power at α = 0.05 to detect a difference in expulsion rates
exceeding 10%. We will enroll a total of 400 women, a suf-
ficient number to allow for changes to intention to leave
the province and thus loss to follow-up using the health
administrative databases. This recruitment will ensure the
final sample is at least the 384 women required to test the
null hypothesis that FlexiT has a significantly inferior
(higher) expulsion rate compared with the NovaT.
Thus, our recruitment will include 400 women who
choose to have IUDs and consent to be randomized to
either the Flexi-T (200 women) or the Nova-T (200
women), and a further 200 who decide to not to use
intrauterine contraception, who will be enrolled as a
non-intervention comparator group. Therefore, a total
of 600 women will be recruited.
The study clinic (see ‘Recruitment facility’, below) pro-
vides abortions to about 700 women meeting the entry
criteria each year, and based on our previous research in
this setting [23] we expect 40% of eligible women to
choose an IUD, and 80% of these to enroll in IUD
groups. Target enrollment is anticipated at 22 months.
Inclusion criteria
All women at participating study sites who have com-
pleted informed consent for an abortion at less than 12
weeks gestational age (as determined by ultrasonography)
and who are residents of the Canadian province of British
Columbia (BC) enrolled in the universal provincial med-
ical services plan are eligible to participate. Additionally,
those who have chosen to use an IUD for post-abortion
contraception are eligible to be randomized to the device
groups. The study has no minimum age criteria for
enrollment.
Exclusion criteria
Women are not eligible if they intend to move from BC
within the next year, if they intend to conceive within 1
year, or if they are currently enrolled in another clinical
trial. The contraindications to the use of an IUD are also
exclusion criteria.
 Uterine cavity anomalies causing distortion of the
endometrial canal including fibroids of more than 50
mm, excluding repaired uterine septum.
 Wilson’s disease.
 Current untreated pelvic inflammatory disease,
cervicitis, or lower genital tract infection.
 Undiagnosed abnormal uterine bleeding.
 Known uterine or cervical malignancy or cervical
dysplasia.
 Bacterial endocarditis.
 Established immunodeficiency (HIV positivity is not
an exclusion unless immunodeficiency is present). Acute malignancies affecting blood or leukemias.
 Recent trophoblastic disease with raised levels of
human chorionic gonatotropin.
Post-randomization exclusion factors for women in
the randomized groups include perforation or excessive
bleeding at the time of their abortion, failure to undergo
the abortion procedure for any reason, or a uterine
anomaly detected at the time of the abortion procedure.
These exclusions are designed to be only those that, in
real-life clinical practice, would preclude a woman from
being able to use an IUD as an immediate method of
contraception.
Recruitment facility
Recruitment for this study will be undertaken at a
teaching-hospital outpatient abortion service in the
Canadian province of British Columbia (BC).
Enrollment process
All women presenting at the study clinic for an abortion
of a pregnancy before 12 weeks gestational age will re-
ceive information via the research study web page [24]
at the time they book their appointment, and a study in-
formation brochure upon check-in. All women will
undergo a post-abortion contraception information ses-
sion with a trained clinic nurse who is not part of the re-
search staff, and the women will decide upon their
contraceptive method of choice before they are asked if
they wish to participate in the study. Interested potential
participants will then be referred for an information ses-
sion with a trained women’s health research assistant
(RA). The RA will explain all study procedures, answer
all questions, and complete the informed consent process
with women before the time of their abortion, including
establishing preferred personal contact methods to ensure
follow-up. Enrolled women will complete an intake ver-
sion of the contraception satisfaction questionnaire (CSQ)
on site. We have previously described the development
and use of the CSQ [23]. Briefly, this is a detailed instru-
ment eliciting the effectiveness of, degree of satisfaction
with, and adverse effects experienced for the range of
contraceptive methods available in Canada. The CSQ has
been adapted from a published instrument [25,26] for use
in post-abortion studies. It has been translated into the
three most common non-English languages in our study
population, and piloted for accuracy and cultural sensitiv-
ity. This trial has been registered at ClinicalTrials.Gov
(Identifier: NCT01174225).
Participants choosing a copper IUD will be rando-
mized to receive either the Flexi-T or the Nova-T. Strati-
fied (that is, separate) randomization lists in sequential
blocks of sizes of eight will be generated for parous
and nulliparous women. Allocation will be performed
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(http://www.randomize.net [27]), to maintain strict con-
cealment. Staff will be kept unaware of the randomization
design and of stratification factors involved, to mitigate
the potential for unblinding of individual blocks. For
women choosing an IUD, the study device determined by
the randomization will be inserted by their surgeon imme-
diately after the abortion and before the worman leaves
the procedure or operating room. Blinding of the surgeon
or the woman receiving the IUD is not possible, as the
IUDs are distinct in appearance. Even once in situ, these
two devices have a differing number and consistency of
strings palpable at the cervical os. Following standard
clinic protocol, all women will undergo PCR testing for
chlamydia and gonorrhea before their abortion, and re-
ceive 2 g metronidazole as a single observed dose as
prophylaxis against postoperative infection [28]. Women
deemed to be at higher risk of a sexually transmitted infec-
tion (STI) [28] and those with positive PCR results will re-
ceive 1 g of azithromycin as well. A post-placement
ultrasound image of the IUD in situ will be recorded.
Participants choosing no contraception and all other
methods of contraception will receive normal instruc-
tions from the facility physician for implementation of
their contraceptive method, undergo the same STI testing
and prophylaxis protocol, and complete an intake CSQ
before leaving the abortion facility.
Enrolled participants will complete the subsequent
CSQ either by mail or as a web-based questionnaire at
3, 6, and 12 months post-abortion. User-friendly inter-
net-based and paper-based formats are available for each
of the four most common languages spoken in our study
population.
All recruited women will receive reimbursement for
their time in the form of a gift certificate at enrollment
and for each completed CSQ submitted. In addition,
women choosing to be randomized to an IUD arm will
receive their device free of charge.
Outcome determination
Primary outcome determination will be through data
obtained from the provincial government health adminis-
trative databases and from the CSQ to determine the ex-
pulsion rate for each group at 1 year. Permission will be
obtained from participants to use personal health numbers
(the unique identifiers used in these databases) and date of
birth to search these databases, detailing all subsequent
care received in BC within the subsequent year (including
IUD removals and re-insertions, and prescriptions for al-
ternate forms of birth control; information on subsequent
pregnancies such as miscarriages, abortions, or deliveries;
and any hospital re-admissions, surgery or prescriptions
dispensed for antibiotics, which may indicate possible
complications). The CSQ will collect data on expulsion ofIUD, effectiveness of and satisfaction with the contracep-
tive method and insertion timing assigned, any removal of
the IUD, any change to contraceptive method or intention
to conceive, any interval pregnancies and their outcomes,
and any adverse events. Using both the databases and the
CSQ methods for outcome determination over a period of
5 years (the device life for the IUDs) we will determine,
with a close to perfect follow-up rate, the intention to
treat (ITT) effectiveness of post-abortion contraception in
Canada.Ethical considerations
This study has received institutional review board
approval from the University of British Columbia-
Children’s and Women’s Research Ethics Board (H10-00798)
and the Interior Health Authority Research Ethics Board
(2010-034).Analysis
Primary outcome will be examined as expulsion rate at 1
year for women randomized to receive the FlexiT device
compared with women randomized to a NovaT. Second-
ary outcomes will be examined annually over the 5-year
period using an ITT framework for both randomized
and non-intervention groups, and will include: preg-
nancy rate, rate for continuation of method, adverse
events (such as infection or perforation), outcomes of
those participants who were chlamydia-positive at the
time of abortion, and satisfaction with contraceptive
method chosen and expulsion rate for years 2 to 5.
Analysis methods
Because our aim is to examine expulsion rates and es-
tablish the non-inferiority (within a margin of 10%) of
the Flexi-T compared with the NovaT, the primary ana-
lysis will be based on an upper (one-sided) 95% confi-
dence limit for the difference in expulsion rates (FlexiT
rate minus NovaT rate). Non-inferiority will be inferred
if the confidence limit value is less than 10%. This sim-
ple approach is valid so long as no systematic difference
in follow-up occurs between groups. As a check, we will
also conduct analysis to account for partial follow-up.
Because our outcome definition is essentially composite
and the relevant risk periods differ by components,
Kaplan-Meier estimates for each component event will
be determined, and composite estimates will be obtained
by summing the estimated cumulative event rates (calcu-
lated as 1 minus the survival function) at the time points
indicated in our operational definitions. Confidence
intervals around the difference in these estimates will be
calculated using the bootstrap method.
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an ITT framework for events occurring within 1year and
within successive years following the abortion, and for
pregnancy events, those associated with a conception
within a year or successive years. Outcomes will be
determined using the CSQ, direct access to clinical
follow-up visit records, and billing and procedure coding
data from the administrative health-system databases.
Multivariate logistic regression will be used to examine
demographic, socioeconomic, and obstetric factors in re-
lationship to primary and secondary objectives.
Survey analysis
The quantitative data from the CSQ will be analyzed
using descriptive and correlational statistics. The CSQ
contains several scales, providing composite scores that
can be used to indicate differences in the secondary out-
comes. Open ended questions will be analyzed through
content analysis, focusing on key topics.
Discussion
Anticipated limitations
Changes in intention to conceive
Owing to our exclusion criteria, we will recruit only
women who do not intend to conceive within the first
year after enrollment. Nevertheless, in this study popula-
tion with an anticipated mean age of 24 years, we fully
anticipate that some women will change their intent to
conceive over the first and subsequent study years. We
will account for this in two ways. First we ask at each
CSQ interview (3, 6, and 12 months) about the partici-
pant’s intent to conceive, and second, we will assume
that randomization will distribute those who have
intended pregnancies within the study period evenly to
both arms of the study.
Expulsions
Most women will be aware when an IUD expulsion
occurs [20], and should it occur, will make arrangements
for alternative contraception. This alternative contracep-
tion may be a replacement device or a change in contra-
ceptive method. Each participant will be provided with a
toll-free number enabling them to contact the principal
investigator (WVN) at any time. In addition, the study
team will monitor follow-up visits, CSQs, government
medical plan billings, and prescription records of alter-
native contraception prescribed or an IUD removed or
inserted. In this manner, we believe we will be able to es-
timate device expulsion rate with a fair degree of accur-
acy. To reflect usual contraceptive conditions most
accurately in the event of an expulsion, we are not
providing a free replacement device. We have stratified at
randomization for parity, as this may be a confounding
factor in expulsion.Contribution
This is the first study to determine the expulsion rate for
the FlexiT380(+) IUD, and to determine if it is non-
inferior to the standard IUD available in Canada, the
Nova-T 200, for post-abortion contraception. In addition,
this study will provide the first ITT evidence on outcomes
for a wide range of contraceptive methods currently avail-
able in Canada, including consumer satisfaction, method
continuation, and pregnancy rates at 1 year post-abortion.
Understanding of satisfaction and effectiveness for com-
mon contraceptive options will better inform efforts to
prevent recurrent unintended pregnancy among Canadian
women.
Trial status
This trial is currently open for enrollment, with the first
enrollments having commenced on 5 October 2010. En-
rollment in the non-intervention group (those women
not choosing to use an IUD) has been slower than
expected but full enrollment is anticipated in late 2012.
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